Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Feb;27(2):743-750.
doi: 10.1007/s43032-019-00080-x. Epub 2020 Jan 6.

Does Adding Fluoxetine to Combined Oral Contraceptives Containing Drospirenone Improve the Management of Severe Premenstrual Syndrome? A 6-Month Randomized Double-Blind Placebo-Controlled Three-Arm Trial

Nesreen AbdelFattah AbdAllah Shehata  1 , Ghada Abdel Fattah Abdel Moety  2 , Hamada Ashry Abd El Wahed  3 , Ashraf Samir Fahim  3 , Maha Ali Katta  3 , Gaber Khalaf Hussein  3
Affiliations
Randomized Controlled Trial

Does Adding Fluoxetine to Combined Oral Contraceptives Containing Drospirenone Improve the Management of Severe Premenstrual Syndrome? A 6-Month Randomized Double-Blind Placebo-Controlled Three-Arm Trial

Nesreen AbdelFattah AbdAllah Shehata et al. Reprod Sci. 2020 Feb.

Abstract

To compare efficacy of combined use of fluoxetine and combined oral contraceptives (COC) versus COC alone in treating severe premenstrual syndrome (PMS), a randomized double-blind placebo-controlled three-arm trial was conducted at Cairo and Beni-Suef University Hospitals. PMS was diagnosed prospectively using the Daily Record of Severity of Problems (DRSP). Three hundred women with severe PMS were randomly divided into three equal groups. Group 1 received oral fluoxetine 20 mg daily in addition to COC containing drospirenone daily for 21 days. Group 2 received COC containing drospirenone daily for 21 days in addition to daily oral placebo. Group 3 received placebo similar to COC and oral placebo similar to fluoxetine. Drug duration was 6 months, and women kept daily records of their symptoms using the Daily Record of Severity of Problems (DSRP) form. The main outcome was the number of women with improved PMS in the final cycle of treatment. Women with improved PMS decreased progressively between groups during last treatment month (65% vs. 50% and 2% respectively; p < 0.0001). Combined use of fluoxetine and COC containing drospirenone is superior to COC in severe PMS.

Keywords: Combined oral contraceptives; Drospirenone; Fluoxetine; PMS-treatment; Premenstrual syndrome.

PubMed Disclaimer

References

    1. Nuckols CC. American Psychiatric Association: diagnostic and statistical manual of mental health disorders. 5th edn, vol. 2. Washington, DC: American Psychiatric Association; 2013. pp. 45–6.
    1. Wittchen HU, Becker E, Lieb R, Krause P. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med. 2002;32:119–321. - DOI
    1. Royal College of Obstetricians and Gynecologists. Green Top Guideline No 48. London: RCOG press; 2007.
    1. Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 2005;106(3):492–501. - DOI
    1. Freeman EW, Kroll R, Rapkin A, Pearlstein T, Brown C, Parsey K, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med. 2001;10(6):561–9. - DOI

Publication types

LinkOut - more resources